Regeneron Prescription drugs, Inc. (NASDAQ:REGN) Wells Fargo 2024 Healthcare Convention September 5, 2024 12:45 PM ET
Firm Contributors
Marion McCourt – EVP, Industrial
Ryan Crowe – SVP, IR and Strategic Evaluation
Convention Name Contributors
Mohit Bansal – Wells Fargo
Mohit Bansal
Nice. So my identify is Mohit Bansal, and thanks for the submit lunch session. So we are going to attempt to maintain it thrilling, only for the submit lunch session. However thanks very a lot workforce Regeneron for becoming a member of us immediately. So we’ve got Marion McCourt with us. She’s the Head of Industrial at Regeneron. And we’ve got Ryan with us. He is the Head of IR. Thanks very a lot for becoming a member of us.
Marion McCourt
Thanks Mohit.
Ryan Crowe
Thanks, Mohit. Perhaps earlier than we soar into questions, I will simply learn our forward-looking assertion, fulfill the attorneys at Regeneron. I wish to remind you that remarks made immediately might embody forward-looking statements of Regeneron and every forward-looking assertion is topic to dangers and uncertainties that might trigger precise outcomes and occasions to vary materially from these projected in such statements. An outline of fabric dangers and uncertainties could be present in Regeneron’s SEC filings. Regeneron doesn’t undertake any obligation to replace any forward-looking statements whether or not on account of new info, future occasions or in any other case.
And with that, we will get began, Mohit.
Query-and-Reply Session
Q – Mohit Bansal
Superior. Nice. So thrilling time at Regeneron. We’re launching high-dose EYLEA and you can be launching just a few extra merchandise with COPD and all coming down the pipe. So there’s rather a lot to speak about. So possibly let’s simply begin with the high-dose EYLEA. How has the uptake been to this point? What you are seeing within the market? And the way do you see this market evolve?
Marion McCourt
So it could be very good to be right here and good afternoon to everyone. So to begin off with some feedback on EYLEA HD, we’re simply previous one 12 months for the reason that launch of EYLEA HD, so in fact, we have reported three quarters to you to this point. I am happy to say that we’re properly on observe to our objective of building EYLEA HD as the brand new standard-of-care, clearly, EYLEA has held that place for a while now.
In the latest quarter, we shared with you the uptake when it comes to internet gross sales of over $300 million, it was a 52% enhance over the prior quarter. In the identical quarter, as , we carried out fairly properly on EYLEA. So collectively, EYLEA HD and EYLEA had been about 45% of the anti-VEGF class. And the mixed merchandise really had been simply over $1.5 billion within the quarter.
So maybe if I am going beneath the numbers somewhat bit as a result of they produce the outcomes. A few issues we’re very acutely aware of is the skilled physicians are having with EYLEA HD, the way it compares to EYLEA, the way it compares to the competitors. And I feel the standout feedback that we get is that it is definitely, the scientific and security outcomes that they’ve come to count on with EYLEA, which they belief, they know very simple to elucidate, modifications in remedy from EYLEA to EYLEA HD sufferers.
However extra importantly, we’re not simply getting switches from EYLEA sufferers, our second supply of switching. EYLEA is the most important, however in fact, the most important product within the class as properly. We’re definitely getting switches from different merchandise, together with fasinumab might be the second most frequent supply of switching, switching additionally from Avastin sufferers the place physicians need enchancment in outcomes, in addition to they’d in all circumstances, when they’re making switches from different therapies.
And as properly, we are also more than happy with what we’re seeing when it comes to uptake for naive sufferers. That is a smaller piece of {the marketplace}, however indicative that EYLEA HD is getting a broad realm of prescribing and a really optimistic doctor expertise.
Mohit Bansal
Nice. So I imply when it comes to — I imply like so clearly, there was a time period then when fasinumab was available on the market and also you, clearly you — it is at all times some strain on incumbent due to that. So there was some gradual decline in market share. So I imply at this level, how do you concentrate on EYLEA plus high-dose EYLEA as class? When it comes to the class, do they maintain the market share? Or do you count on that to develop market share as properly?
Marion McCourt
In order we take a look at general efficiency within the market, as , Regeneron and we attempt to keep away from future steerage or predicting future market shares. What I’ll share with you is I feel we’ve got a tremendous product when it comes to alternative for physicians to lastly maintain the scientific outcomes, the protection outcomes, however get to true sturdiness, and we’re seeing that true sturdiness come for with EYLEA HD. In order that’s very optimistic.
Actually, we’ve got numerous skilled people at Regeneron, our medical workforce, our industrial workforce, all of the totally different areas of business, whether or not reimbursement, the gross sales pressure, our reimbursement specialists are all doing a very good job with an viewers that they know properly, our ambition will at all times be to carry out in addition to attainable within the market. We do imagine in doctor alternative, however we’re actually happy with the uptake that we’re seeing with EYLEA HD whereas additionally preserving a really sturdy EYLEA market.
Mohit Bansal
Received it. No, that is smart. After which — so I feel you talked about 20% of switches final quarter got here from the [indiscernible]. So do you — may you give us some sense why these sufferers are switching?
Marion McCourt
Nicely, that at all times is an fascinating query. And candidly, I can not recall if it was precisely 20%, however I do know it is in that vary, a few factors right here or there. What physicians are on the lookout for after they change a affected person is an enchancment, both within the scientific response of the affected person, often you make a change since you are simply not seeing the extent of enchancment, whether or not it’s visible acuity, whether or not it’s drying, you need one thing that gives sufferers one thing extra.
One other level of dissatisfaction might be you’ve got made a change since you’re hoping to get to higher sturdiness and you are not getting there. So that may be the sort of issues that we’d see in case research. I might additionally share that as physicians use extra on EYLEA HD and we’re happy with the quantity, not solely of the — and also you at all times have some physicians who’re increased customers out of the gate, some come alongside at sort of the following tempo. We do see depth and breadth of prescribing rising, which is de facto good. And the notion in addition to, as individuals, physicians and their sufferers see extra nice outcomes. They develop into increasingly more assured, they usually begin to use the product in a higher manner. However clearly, you make a change once you really feel you possibly can be extra happy with one other product on this case, EYLEA HD.
Mohit Bansal
Received it. That is smart. After which there are some questions we get on the general market development for VEGF market. So I imply there may be clearly VEGF market and there is branded VEGF market. You talked about that you simply’re getting some share from [indiscernible]. So are you able to speak somewhat bit in regards to the general VEGF market in addition to branded market? Up to now, there have been occasions when it was actually excessive single digit 8%, 9%. However once more, I imply, how do any can’t forecast that. However — how — what are you seeing proper now? Has the development slowed down somewhat bit? Or do you see an analogous degree of development that you simply noticed up to now 12 months?
Marion McCourt
So what I might say is that if you happen to return over the past 4 or 5 years, there was somewhat little bit of bouncing round as a result of we had the time period, it looks as if a very long time in the past now, however the pandemic time period, the place typically you’ll see decreases adopted by will increase. After which how does all that kind out. What I’d say, is that definitely the anti-VEGF class is a really wholesome one when it comes to growing older inhabitants, which is nice, maybe issues of diabetes which is not pretty much as good, however there are numerous sufferers coming to the fold — for potential therapy. I might say, general, in all probability we see a continuity within the market of mid-single-digit kind development, however it’s laborious to foretell for the long run. And I am simply providing you with some averages over years if I had been to look traditionally.
Mohit Bansal
Received it. That fully is smart. After which additionally from the EYLEA HD viewpoint, in the true world what dosing pursuits, in all probability like now one 12 months, like what sort of dosing interims you might be altering in the true world?
Marion McCourt
So the vital factor on the EYLEA HD dosing intervals and we take a look at a complete number of totally different knowledge sources, and I am positive that there can be increasingly more info that shared at a few of the main Regeneron conferences from the rostrum as properly. However the principle takeaway can be that after the loading doses, in order that’s three loading doses usually for a brand new affected person each 4 weeks. Extra regularly, physicians are in a position to get out and prolong, maybe seven weeks, 8 weeks, 10 weeks and so forth. And it’s one thing that they have not seen earlier than with different merchandise, and it’s making a significant distinction for his or her sufferers.
There are additionally circumstances the place physicians will change sufferers who would possibly already be in a dosing interval, for instance with EYLEA at 6, 7, 8 weeks, they usually wish to take them out to an extended dosing interval, they could determine to reload, however typically understandably, sufferers don’t desire extra injections of their eye, so they may take them from that time and begin to prolong them as properly. So there are a number of various circumstances, however the principle takeaway level is that physicians are experiencing the extent of sturdiness to a higher extent than they’ve seen earlier than.
Mohit Bansal
Received it. After which — so I imply, general when you may have — so within the final one 12 months, the tempo of conversion versus your preliminary expectations, the place would you rank it? Such as you suppose it’s consistent with expectations? Or do you suppose it’s going higher than expectation?
Marion McCourt
Sure. I feel it’s in step with what we shared in what we’re working in direction of is making EYLEA HD a standard-of-care. I feel the proof supply for all of you is to have a look at the numbers and simply take a look at the trajectory of efficiency that we’re exhibiting for every of our accomplished quarters with EYLEA HD and simply take a look at different merchandise which have extra just lately come into {the marketplace} and the truth that we’re a step forward.
Having stated that, I by no means wish to be happy, and I’ve a workforce that is similar to me when it comes to ambition of efficiency, and we actually do suppose that EYLEA HD provides sufferers a possibility to have higher therapy, and definitely their retina specialists agree with that notion however for the precise sufferers, which candidly is almost all of sufferers, fewer injections within the eye is an effective factor. Usually, it requires a affected person having caretaker household mover. There’s an nervousness that goes alongside naturally for anybody having an injection not to mention of their eye. So this is a crucial attribute of their therapy.
Mohit Bansal
One final query on this, I promise.
Marion McCourt
I can speak about EYLEA HD all day lengthy.
Mohit Bansal
Truly. When it comes to prefilled syringe, the place do you stand? And I imply what are the timelines there?
Marion McCourt
Certain. So I am actually blissful to report that the EYLEA HD prefilled syringe is on observe to be in market by 2025, by early 2025. And I feel it is vital as a result of this really would be the quickest, together with our personal firm. It took us longer to have EYLEA prefilled syringe in market after launch of the vials. So we’re on tempo to be on the quickest finish of that chance coming collectively.
Mohit Bansal
Superior. On that top be aware, we are going to simply change gears to different small product, you may have referred to as DUPIXENT. So I imply I feel possibly let’s simply speak about AD first, atopic dermatitis first, earlier than we transfer into COPD. So I imply, like clearly like it is a query we get — we ask yearly like now you may have carried out so properly in atopic dermatitis, like, the place would the expansion come from? How far more market growth alternative there may be? And might you speak somewhat bit about that?
Marion McCourt
Certain. So it truly is outstanding that DUPIXENT, clearly with the breadth of indications throughout age ranges for atopic dermatitis, adults, adolescents, peads, sufferers down as younger as 6 months of age, which is actually outstanding. However even with all that and the uptake and the standard-of-care, our KOLs typically referred to, DUPIXENT is first and finest in class, which is fantastic to listen to them say that. However we nonetheless have in all probability solely gotten to about possibly mid-teen percentages of the affected person alternative. So there may be nonetheless a considerable unmet want within the market, however definitely, we’re making nice progress in atopic dermatitis.
It’s also actually vital so as to add as physicians are taking a look at treating sufferers, the arrogance they’ve now in their very own expertise in treating atopic dermatitis sufferers. I’m at all times struck by one of many KOLs in New York, he mentions to me each time I see him how his atopic dermatitis sufferers was probably the most troublesome sufferers that got here into his follow years in the past, roughly like six years, seven years in the past as a result of he had little or no for them they usually had been emotional, they weren’t in a position to sleep, not in a position to work in addition to they want — like all kinds of points of their life had been interfered with, typically for kids or adolescents, they had been home-schooled.
And now the identical physicians, the identical doctor specifically, will say these are his finest affected person experiences as a result of with DUPIXENT, it was a remark additionally, I am providing you with an [N1] (ph), but when it does not reply, then it is not atopic dermatitis, like the extent of success that physicians are attaining is to profound, however we nonetheless have an extended strategy to go.
And I feel with Sanofi, we have been in a position to set up DUPIXENT a really profitable product, not solely in AD however this capability to impression kind 2 illness is so vital, and that is one thing that different merchandise do not essentially have out there immediately or people who hope to be out there sooner or later, not solely the twin mechanism of motion of DUPIXENT, but additionally the power to have impression in kind 2 cascade, which is why we see the success in indications like bronchial asthma, nasal polyps, eosinophilic esophagitis and the listing goes on.
Mohit Bansal
Superior. No, that is outstanding. When it comes to — there may be some competitors coming down the road with clearly lebrikizumab is coming after which there are some OX-40s as properly. So how do you — type of once you speak to physicians, how do you see these as competitors?
Marion McCourt
Proper. Sure. So there are a few issues. Extra merchandise in market may need some positivity when it comes to bringing sufferers into the therapy continuum. So that may be a reality to be thought-about. That is good for sufferers. However I additionally suppose that the notion of DUPIXENT which is now established and has this view of being first and finest. And it is an earned view. It is not simply the expertise in market, the efficacy, the protection and the breadth of use. However it’s also this notion of a twin mechanism of motion, which different merchandise haven’t got. Actually, out there immediately, there’s one other product that’s anti-IL-13 does not have the 4 element clearly does not have the opposite indications and a few would say isn’t higher and even probably pretty much as good as DUPIXENT in atopic dermatitis.
So competitors is nice for a wide range of causes, however I feel we’ve got a really compelling profile in DUPIXENT that takes us properly into the long run, and we’ll definitely proceed our aggressive readiness as we’ve got in years previous. And positively be sure we’re doing the precise issues when it comes to bringing DUPIXENT to physicians and sufferers.
Mohit Bansal
How sturdy an argument this month-to-month goes enhance from IL-13?
Marion McCourt
Nicely, it’s totally fascinating. And I feel one of many questions is, will month-to-month dosing be attainable for the sufferers who want it, that means labels for these merchandise are typically average to extreme. And what’s most vital is that you’ve a product that is ready to assist maintain that ache, that itch, that folks — if you happen to guys keep in mind a few of our first TV ads, we had one, there was somewhat edgy with ants crawling on somebody’s pores and skin. I am advised that as atopic dermatitis is sort of reemerging, that is what it begins to really feel like. So sufferers can sort of really feel it properly sufficient.
So using each two week dosing with DUPIXENT definitely has been one thing that is been very properly obtained, very tolerable. However the #1 merchandise is ensuring that sufferers have persevering with reduction. They do not have illness exacerbation or illness breakthrough on their pores and skin, which is extremely distressing for them as a result of they know as soon as it begins, it creates sort of this cascade and it retains going. And typically sufferers will report that it comes again worse than after they beforehand handled it.
Mohit Bansal
Received it. That is very useful. So possibly shifting on to COPD. So possibly if there’s a manufacturing replace or any replace you may have at this level?
Ryan Crowe
Certain. Sure. The FDA requested knowledge from many subpopulations of the Discover in Berea research again in, I assume it was late April, early Might time-frame. And we responded to that. They thought-about our response to be a significant modification, which resulted in a 3-month delay to our authentic PDUFA, which was June 27.
So the present PDUFA sits at September 27. We’ve been corresponding with the FDA as a part of the conventional course. And I feel we’re on observe for his or her resolution to return by the top of this month. And hopefully, that call is for an approval. We do not imagine that the subpopulations generated any sort of knowledge that may recommend any of them drove the results of both research, it was very balanced and just about throughout the board profit for practically each subgroup. So we’re excited in regards to the hopefully, upcoming launch. And I am positive Mary and his workforce can be prepared and desirous to get began.
Mohit Bansal
No, that is — I feel I crossed that linvo. That is why I requested [indiscernible], however regulatory replace. However thanks for that. So no — when it comes to industrial, I imply like — since you are already in bronchial asthma. So that you’re in all probability going to clinics already. So how a lot does it assist with the industrial half when you may have the product already in the identical clinics?
Marion McCourt
Proper. So no query the expertise that pulmonologists have already had with DUPIXENT and different treaters realizing the product, in fact could be very optimistic and data that so many sufferers have been handled clearly, approaching over 1 million sufferers handled, that is very optimistic throughout the age ranges, geographies. It provides numerous confidence.
However there is definitely, for each launch, you put together particularly for that launch, for that inhabitants of physicians, sufferers, schooling, ensuring they perceive, and it is a huge deal as a result of there hasn’t been a biologic for therapy of COPD sufferers. After all, I am speaking in regards to the eosinophilic COPD sufferers, which is a big inhabitants. it’s about 300,000 within the US about 500,000, if I take a look at G7, that is actually a significant alternative for therapy occasions.
Many of those sufferers are on triple remedy immediately, not getting the extent of efficacy that they want however definitely for preserving physicians to have had expertise with DUPIXENT in a really optimistic expertise, we immediately, as — are the product that has the best new to model prescriptions in biologic bronchial asthma. It’s a aggressive class, however their expertise has been optimistic. There are some educational facilities, for instance the place there could also be physicians that specialize solely in COPD, there they definitely know and maybe have had data of colleagues utilizing DUPIXENT or maybe they too are treating bronchial asthma sufferers, however there can be — some extra schooling can be crucial.
To your secondary level associated to product availability, that too clearly, is a plus bringing a brand new essential indication into {the marketplace}. The place we are going to work laborious, although, is to determine payer protection and affordability for this COPD inhabitants of sufferers, which definitely have, in some cases, half D protection, in some circumstances, industrial protection. And within the meantime, we clearly have already got an approval in Europe. Germany has DUPIXENT accessible for COPD immediately. It’s extremely early days, as I discussed within the earnings name. However up to now, the suggestions and commentary to us has been very optimistic.
Mohit Bansal
Superior. No, that is very useful. Thanks for that. I imply I feel one query I wish to ask you, Ryan. I imply, what — is there a time line to consider when may we see the CMA plus DUPIXENT knowledge evaluation?
Ryan Crowe
In order that’s an thrilling program that we launched this 12 months in meals allergic reactions, extreme meals allergy. And the biologic rationale is that you simply see sufferers immunoglobin switching from IgGs to IgEs. So with the BCMA routine, which we hope is a brief one, a brief course, you are depleting your whole IgEs undetectable ranges and then you definately use DUPIXENT to keep up these IgE ranges at undetectable.
So the — we’re starting the enrollment of a really small research of 6 sufferers and we nonetheless hope to have preliminary IgE knowledge from preliminary sufferers by the top of this 12 months after which persevering with to comply with extra sufferers into 2025 to hopefully present that we will really treatment meals allergic reactions or reverse meals allergic reactions.
After a sure time period, I imagine it’s 30 weeks submit the final linvoseltimab dose, sufferers could have an non-compulsory meals problem. And that is sort of the final word take a look at, proper to see if they’ll stand up to what was beforehand one thing that brought on a extreme allergic response. So we’re excited in regards to the strategy. It’s extremely novel and modern. It makes use of two Regeneron developed antibodies, and we’re actually optimistic this will change the best way allergic reactions are managed.
Mohit Bansal
And we may see non-compulsory meals problem knowledge later this 12 months?
Ryan Crowe
No, I do not suppose we’ll see the non-compulsory meals problem knowledge this 12 months simply because it takes a while for us on the upkeep routine earlier than they’re going to be allowed to enter the 5 month. We’ll be on the lookout for IgE knowledge, probably allergen, pores and skin prick checks this 12 months in a affected person or two with extra complete knowledge to return subsequent 12 months.
Mohit Bansal
Received it. No, that is tremendous useful. Perhaps like once more, oncology is one other space the place, given LIBTAYO, you might be behind the leaders. Initially, individuals didn’t provide you with numerous credit score, however once more, LIBTAYO is doing properly now. So I imply it is a blockbuster product, after which you may have different stuff coming. So how do you — like once you take a look at that portfolio, how do you concentrate on the portfolio and development? After which for [linvoseltamab] (ph)– sorry for [indiscernible], mixture, how vital it’s to have [beta data versus Opdualag versus non-inferiority?
Ryan Crowe
So that’s a great question and one that we constantly are thinking about at Regeneron, how do we differentiate ourselves through the development programs. And when we come to market with certain data in our label that we think can give us a competitive advantage. Because at the end of the day, in oncology, we really firmly believe that data will sell your product. So in the case of LAG-3, maybe I’ll start with that, we have generated across three independent cohorts in metastatic melanoma, very impressive response rates that are in the low to mid-60% range and PFS results, median PFS results that have so far exceeded that of PD-1 monotherapy as well as the Opdualag.
So we’re excited to see what the Phase III data looks like next year, which uses pembrolizumab as the control. So we’ll be testing Inmazeb plus LIBTAYO versus pembro-monotherapy. We also have a head-to-head study underway that combines our Inmazeb LIBTAYO and compares it to Opdualag, the approved LAG-3 PD-1 combination from Bristol-Myers. That trial just got underway and we’ll be enrolling — we are enrolling now and hope to get data, I think in 2026.
The primary endpoint there is objective response rate. We’ll also be evaluating PFS and OS. One thing that we’re really hopeful for in the KEYTRUDA-controlled study is to achieve overall survival, which was an endpoint that Opdualag missed in its metastatic melanoma program. And really, I think is an important one that if we can demonstrate we’ll differentiate us beyond just the head-to-head data we hope to generate.
Marion McCourt
I’ll just add, you started reporting the question related to LIBTAYO. So just a quick shout out on LIBTAYO. To your point, now blockbuster brand in the marketplace. We have full rights to LIBTAYO, which is exciting for the Regeneron team and certainly continue to be standard of care for the skin indications in cutaneous squamous cell carcinoma and also in basal cell carcinoma.
And I’m pleased to report as well, as you know that we are seeing certainly growth in that area, but also in the lung cancer indication for mono and chemo combo patients, both coming from community and also the academic setting. And obviously, on a worldwide basis now as we are commercializing and burning all aspects of LIBTAYO on a worldwide basis with a focus on the larger international markets.
Mohit Bansal
Great. So I mean, in the last few minutes, two key pipeline assets, which we get a lot of questions on. I think — so I want to talk about IL-33, as well in COPD next year. How should we think about that asset? And what is your confidence level in terms of data in the next year?
Ryan Crowe
So IL-33 is an antibody we call itepekimab. And I don’t blame you for using IL-33 instead. Not an easy one to pronounce. But we’re very excited about it. We have generated Phase II data that has shown a 42% reduction in annualized exacerbation rates among former smokers regardless of eosinophilic status. So this is sort of in an all-comers population, which has been very hard to address. So we are very encouraged by that, but we’re also encouraged by the genetic data that shows that patients with loss of function of IL-33 have a much lower incidence of COPD.
So we think it’s a very fundamental driver of the disease and our antibody is going to be able to block it very effectively and hopefully will drive great results for us. We do expect that data next year as part of the Sanofi antibody collaboration. So both us and Sanofi are very encouraged by the data we’ve seen, the genetics that support it and look forward to the readout mid next year.
Mohit Bansal
Got it. And then since you are not including current smoker, then which is the patient at this point, right?
Ryan Crowe
Yes. I mean we did not see the same magnitude of treatment effect in the Phase II study among current smokers. It is unclear to us exactly why that was the case. And we actually do have a small cohort within these AERIFY programs that will look at current smokers, just to take a second look and make sure. But I don’t know — we don’t have any current plans to move that forward with the registration enabling study.
Mohit Bansal
Got it. And then the other one, is definitely myostatin, which we hear a lot about. So I mean, what are your current thoughts there? And then I think I do want to ask about the dosage, the doses — the dose is pretty big there. So I mean, like how are you thinking about — obviously, we’ll have data next year probably, right? So — how are you thinking about long-term development plan there?
Ryan Crowe
So yes, our approach to obesity is a bit different than that of the current incumbents in the market where we’re not focused on sort of a food aversion therapy. We’re rather focused on muscle and metabolism. We know that myostatin is a key negative regulator of muscle growth and that by blocking it, we hope to allow patients to lose more weight, maintain their lean muscle mass, maintain their metabolic rates and make — and generally, once they discontinue therapy on an incretin-based therapy and maintain the weight loss better.
So that is sort of the goal of the Phase II proof-of-concept study that we’ve initiated. As you mentioned, we should get data probably second half of next year, at least on the primary endpoint which will evaluate total weight loss as well as percent of fat loss. The second 26-week phase of the study will continue from there, which will look at half the patients dropping semaglutide and all the patients dropping semaglutide and half the patients maintaining myostatin monotherapy. And that will really give us a very good indication about whether this will be an effective maintenance therapy.
We think maintenance is important because we know that a lot of patients cannot tolerate these drugs, do not tolerate these drugs and discontinue them within a year, and I’m speaking primarily about semaglutide and tirzepatide. They just — patients don’t feel great. There is a lot of GI toxicities associated with them, so they stop taking them. And one happens when they stop, they regain the weight. So we hope that because of anti-myostatin very benign safety and tolerability profile that patients can maintain their weight loss and stay on the drug. So we will get those answers next year, and we are excited about the potential there in obesity to really improve on the very impressive results that these other therapies have been able to generate.
Mohit Bansal
Awesome. So one last question. Fast forward one year, 2025 September. I hope you are here. So what would make you look back at this year and then as that year pass and you say it is a great year for us.
Marion McCourt
So definitely would love to be here next year. And I think the — it will be around the items that we’ve discussed today. It will be the ongoing performance of EYLEA HD in the marketplace. We will also have an opportunity in DUPIXENT to bring additional indications as we discuss for the marketplace. We’ll have new indication launches across the portfolio. We hope to have product launches in hematology, which we very much look forward to.
And then to a lot of the discussion today over the course of that 1 year time, I think we’ll see a lot of them — in terms of clinical readouts in our future product portfolio coming to all of you. So a lot to look forward to this year and certainly a very ambitious team to follow through on those goals.
Ryan Crowe
Maybe I’ll jump in on some of the pipeline highlights that we hope for next year in 2025. I can think of a few. I mean we’ve talked about a couple. Itepekimab, the pivotal studies for that should read out. We’ll get our initial data in obesity with the myostatin and active NA programs combined with semaglutide. We should also get pivotal data for LAG-3 in melanoma. And of course, by the end of this year, we should also see our first data in lung cancer for [Inmazeb] (ph) LIBTAYO, which clearly may open up a complete one other alternative in a distinct and huge stable tumor.
And lastly, the allergy knowledge. We should always proceed to generate and hopefully have extra sturdy knowledge by this time subsequent 12 months to see what that routine might appear to be for sufferers and making an attempt to reverse their extreme meals allergy. So numerous — very fascinating readouts coming within the subsequent a number of months. After which by this time subsequent 12 months, hopefully, they’ve all learn out efficiently. And we’re on to the following wave of innovation at Regeneron.
Mohit Bansal
Perhaps you launch a few of the knowledge on the morning of.
Ryan Crowe
We’ve carried out that previously. Sure, EYLEA HD’s preliminary pivotal knowledge, we introduced right here two years in the past.
Mohit Bansal
Superior. On that top be aware, thanks very a lot for becoming a member of us.
Marion McCourt
Thanks, viewers. Thanks, everybody.
Ryan Crowe
Thanks.
